Management Team

Paul A. Friedman, M.D.

Executive Chairman

Paul has served as Executive Chairman since October 2014 and as a director since January 2014. From 2001 to January 2014, he was Chief Executive Officer of Incyte Corporation, a public biotechnology company, and he served as President of Incyte from 2004 to January 2014. From 1998 until 2001, Dr. Friedman was President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a Diplomate of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation. Dr. Friedman is a director of Incyte, public biopharmaceutical companies Auxilium Pharmaceuticals, Inc. and Durata Therapeutics, Inc. and private biopharmaceutical company Gliknik, Inc. Dr. Friedman was a director of Bausch & Lomb Incorporated from 2004 until its acquisition in 2007 and was a director of Sirtris Pharmaceuticals, Inc. from March 2008 until its acquisition in June 2008. Dr. Friedman received his A.B. from Princeton University and his M.D. from Harvard Medical School.

Christopher D. T. Guiffre, J.D., MBA

Chief Operating Officer

Chris has served as our Chief Operating Officer since October 2014. He served as Senior Vice President and Chief Business Officer from 2012 to 2014. Prior to that, Mr. Guiffre held a number of senior executive positions at various biopharmaceutical companies. From 2010 to 2012, he served as President and Chief Executive Officer of Alvos Therapeutics, Inc.; from 2008 to 2009, he served as Chief Business Officer at Hydra Biosciences, Inc.; and from 2001 to 2008, he served as a senior executive at Cubist Pharmaceuticals, Inc., most recently as Senior Vice President, General Counsel and Secretary. From 1997 to 2001, Mr. Guiffre held several positions at Renaissance Worldwide, Inc., including Vice President, General Counsel and Clerk.

Prior to that, he was an Associate at Bingham, Dana & Gould LLP (now known as Bingham McCutchen LLP). Chris received a B.S. degree from Babson College, a J.D. from Boston College Law School, and an M.B.A. from Boston College Carroll School of Management.

Edward Garmey, M.D.

Chief Medical Officer and Senior Vice President

Edward has served as our Chief Medical Officer and Senior Vice President since 2011. Prior to joining Cerulean, Dr. Garmey held a variety of positions at ArQule, Inc., a clinical-stage biotechnology company, including as Vice President for Clinical Development since 2008, and as Clinical Development Liaison from 2007 to 2008. From 2006 to 2007, Dr. Garmey served as Medical Director at GPC Biotech, a German biopharmaceutical company and now a subsidiary of Agennix AG, where he helped oversee global clinical development studies.

Dr. Garmey received his A.B. from Harvard University and his M.D. from New York University. He is a member of the Scientific Advisory Board for the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative, and he serves on the Board of Visitors of Hearth, a Boston-based non-profit organization dedicated to the elimination of homelessness among the elderly.

Karen Roberts

Senior Vice President, Finance and Administration

Karen has served as our Senior Vice President, Finance and Administration since 2010. Prior to joining Cerulean, from 2001 to 2009, Ms. Roberts served as Vice President, Finance and Administration of Elixir Pharmaceuticals, Inc., a biopharmaceutical company where she was the senior financial executive responsible for all aspects of finance, accounting and administration. From 1998 to 2001, Ms. Roberts served in a number of roles, including Corporate Controller and Chief Accounting Officer and Vice President, Finance, at Frontline Group, Inc., a provider of business performance improvement services and products. Prior to that, Ms. Roberts served as Director of Finance at Dyax Corp., a biotechnology company, and as Corporate Controller and Director, Financial Administration at T Cell Sciences, Inc., a biopharmaceutical company.

Ms. Roberts received her B.S. in Business Administration with a concentration in accounting from Salem State College.

Alejandra Veronica Carvajal, J.D.

Vice President, General Counsel

Alejandra has served as Vice President and General Counsel since 2014. Prior to joining Cerulean, Ms. Carvajal held a variety of positions at Millennium: The Takeda Oncology Company, including most recently as Associate General Counsel. Ms. Carvajal joined Millennium in 2004 as a senior attorney and enjoyed over ten years of increasing responsibilities relating to all aspects of oncology drug development. Prior to joining Millennium, Ms. Carvajal was an attorney with the law firms Day, Berry & Howard, and Hill & Barlow.

Alejandra received a B.A. cum laude from Harvard University and a J.D. cum laude from Georgetown University Law Center.

Scott Eliasof, Ph.D.

Vice President, Research

Scott has led our research team since 2007 and has served as Vice President of Research since 2011. Previously, he was the director of the Chemical Biology Platform at the Broad Institute, directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science, and software engineering. This interdisciplinary organization is closely affiliated with the laboratory of Stuart Schreiber from Harvard University and is one of the largest and oldest academic screening centers in the country. Prior to joining the Broad Institute, Scott worked at Millennium Pharmaceuticals, where he managed scientific teams in cell biology, molecular biology, neuroscience, and bioinformatics for a large-scale genomics-based drug discovery program. Earlier in his career, Scott was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders.

Scott earned his B.S. from MIT in Electrical Engineering, Ph.D. from the University of California at Berkeley in Neuroscience, and completed his post-doctoral fellowship at the Vollum Institute in Portland, Oregon.

Pamela Strode, MS

Vice President, Regulatory Affairs

Pamela has served as Vice President, Regulatory Affairs since 2014. Ms. Strode has over 25 years of in-depth regulatory experience. Prior to joining Cerulean, she spent approximately 20 years in positions of increasing responsibilities, most recently as Executive Director, in Drug Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. Prior to Boehringer Ingelheim, Ms. Strode worked in regulatory affairs for 6 years at Bristol-Myers Squibb and previously worked in research and development there and at Hoffmann-La Roche.

Pamela received a B.S. in Microbiology from Cook College at Rutgers University and a M.S. in Quality Assurance and Regulatory Affairs from Temple University.

Marc Wolfgang, MS

Vice President, Pharmaceutical Sciences and Manufacturing

Marc has led our analytical team since 2007 and has served as Vice President of Pharmaceutical Sciences and Manufacturing since 2011. Previously, he was senior director of quality at Momenta Pharmaceuticals, where he was responsible for building the quality affairs and quality control functions, including the establishment of an in-house cGMP testing laboratory. Prior to joining Momenta, he held various CMC related positions ranging from analytical development, QA/QC, production technology, and regulatory affairs at Millennium Pharmaceuticals, Biogen, and Boehringer Ingelheim.

Marc earned a BS degree in Biology from Pennsylvania State University and a MS degree in Chemistry from Montclair State University.